

## 25-hydroxyvitamin D<sub>3</sub> may Function via Genomic and Non-Genomic actions

Hirota Y<sup>1\*</sup>, Suhara Y<sup>2</sup>, Osakabe N<sup>3</sup>, Sakaki T<sup>4\*</sup> and Okano T<sup>5\*</sup>

<sup>1</sup>Laboratory of Biochemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan

<sup>2</sup>Laboratory of Organic Synthesis and Medicinal Chemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan

<sup>3</sup>Food and Nutrition Laboratory, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan

<sup>4</sup>Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Kurokawa, Imizu, Toyama 939-0398, Japan

<sup>5</sup>Department of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan

\*Corresponding authors: Yoshihisa Hirota, Laboratory of Biochemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan, Tel: +81-48-7201-6037; Fax: +81-48-7201-6011; E-mail: [hirotay@shibaura-it.ac.jp](mailto:hirotay@shibaura-it.ac.jp)

Toshiyuki Sakaki, Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Kurokawa, Imizu, Toyama 939-0398, Japan, Tel: +81-766-56-7500; Fax: +81-766-56-2498; Email: [tsakaki@pu-toyama.ac.jp](mailto:tsakaki@pu-toyama.ac.jp)

Toshio Okano, Department of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan, Tel: +81-78-441-7524; Fax: +81-78-441-7524; Email: [t-okano@kobepharma-u.ac.jp](mailto:t-okano@kobepharma-u.ac.jp)

Received Date: July 25, 2016; Accepted Date: July 29, 2017; Published Date: July 31, 2017

Copyright: © 2017 Hirota Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Keywords:** Vitamin D; 25D<sub>3</sub>; 1 $\alpha$ ,25D<sub>3</sub>; VDR; CYP27B1; Genomic action; Non-genomic action

### Abbreviations

25D<sub>3</sub>: 25-hydroxyvitamin D<sub>3</sub>; 1 $\alpha$ ,25D<sub>3</sub>: 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>; CYP27B1: 25-hydroxyvitamin D 1 $\alpha$ -hydroxylase; VDR: vitamin D receptor; RXR: Retinoid X receptor; VDRE: Vitamin D responsive element.

### Commentary

Vitamin D<sub>3</sub> ingested from food or produced in the skin binds to the vitamin D binding protein (DBP) in the blood. Vitamin D<sub>3</sub> bound to DBP is carried to the liver and hydroxylated at position 25 by CYP2R1 or CYP27A1, belonging to the cytochrome P450 (CYP) superfamily, resulting in 25-hydroxyvitamin D<sub>3</sub> (25D<sub>3</sub>). 25D<sub>3</sub> binds to DBP and circulates through the blood; in the kidney, it binds to megalin, is highly expressed in the renal proximal tubule, and is taken up by endocytosis [1]. 25D<sub>3</sub> incorporated into cells together with DBP is hydroxylated at the 1 $\alpha$  position by CYP27B1, resulting in 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> (1 $\alpha$ ,25D<sub>3</sub>). 1 $\alpha$ ,25D<sub>3</sub> circulates through the blood and binds to vitamin D receptor (VDR) in organs with VDR expression, such as the bone, small intestine, and kidney [2]. VDR forms a dimer with retinoid X receptor (RXR) and binds to vitamin D response elements (VDRE) upstream of the target gene promoter [3,4]. As a result, vitamin D interacts with various transcription coupling factors and basic transcription factors to activate promoters and regulate gene expression [5]. 1 $\alpha$ ,25D<sub>3</sub> plays an important role in the maintenance of calcium homeostasis, bone formation, and differentiation of cells by genomic action, i.e., by controlling the expression of the target genes, mainly via VDR. However, in recent years, rapid, non-genomic action that does not involve protein synthesis has been reported. Specifically, 1 $\alpha$ ,25D<sub>3</sub> activates the intracellular signaling molecule present in the membrane via caveolae, structural functional components of the cell membrane, and


membrane-associated rapid response steroid (MARRS) binding protein, and liberates a second messenger [6,7]. It has been reported that such non-genomic action leads to physiological activities, such as insulin secretion and smooth muscle cell migration. These previous findings have indicated that vitamin D exerts various physiological effects by genomic and non-genomic action.

The expression of CYP27B1, a key enzyme that makes 1 $\alpha$ ,25D<sub>3</sub>, is suppressed by 1 $\alpha$ ,25D<sub>3</sub>. In contrast, the enzyme CYP24A1 inactivates 1 $\alpha$ ,25D<sub>3</sub> and is induced by 1 $\alpha$ ,25D<sub>3</sub>. Accordingly, the 1 $\alpha$ ,25D<sub>3</sub> concentration in the blood is kept fairly constant. Based on these observations, 1 $\alpha$ ,25D<sub>3</sub> is referred to as "active vitamin D<sub>3</sub>" and is thought to be a true VDR ligand. On the other hand, 25D<sub>3</sub> is considered a "precursor of active vitamin D<sub>3</sub>" because its affinity for VDR is several hundredths that of 1 $\alpha$ ,25D<sub>3</sub>. However, many observations cannot be explained if only 1 $\alpha$ ,25D<sub>3</sub> is regarded as active vitamin D<sub>3</sub>. For example, the L99P mutation in CYP2R1 causes rickets [8]. The 25D<sub>3</sub> concentration (approximately 10 nM) in the blood of individuals who are homozygous for this mutation is markedly lower than that of healthy people (30 to 120 nM). Blood calcium and phosphorus levels are also low, and the blood alkaline phosphatase concentration is abnormally high, i.e., 10 times that of healthy people. However, the concentration of 1 $\alpha$ ,25D<sub>3</sub> in the blood of patients is normal, and this result is difficult to understand.

Vitamin D is deeply involved in bone metabolism, cell differentiation and proliferation, and immunity, and is closely related to various diseases, such as osteoporosis, cancer, diabetes, arteriosclerosis, and autoimmune diseases [9]. The 25D<sub>3</sub> concentration, but not the 1 $\alpha$ ,25D<sub>3</sub> concentration, in the blood is a disease indicator. The affinity of 25D<sub>3</sub> for VDR is remarkably low, about 1/500 times that of 1 $\alpha$ ,25D<sub>3</sub>, but, inversely, the blood concentration is nearly 1000 times higher. These facts suggest that 25D<sub>3</sub> itself may act directly as a ligand for VDR. Additionally, several papers have suggested the importance of direct action of 25D<sub>3</sub> [10,11].

Munetsuna *et al.* added 25D<sub>3</sub> at a final concentration of 10 nM or 100 nM to the medium of human prostate-derived PZ-HPV-7 cells, and observed incorporation of 25D<sub>3</sub> into cells, metabolism of 25D<sub>3</sub>, and intranuclear translocation of VDR and CYP24A1. Induction of the transcription of VDR target genes and cell proliferation were measured over time. They also investigated the effects of VDR and CYP27B1 using siRNA [12]. They found that the ratio of intracellular/extracellular abundance of 25D<sub>3</sub> reached an equilibrium within 10 minutes, VDR nuclear translocation was nearly complete in 90 minutes, CYP24A1 transcription was induced beginning at 120 minutes, and significant metabolism of 25D<sub>3</sub> by CYP24A1 occurred after approximately 300 minutes [13]. HPLC using tritium-labeled 25D<sub>3</sub> showed a faint peak at the elution position of 1 $\alpha$ ,25D<sub>3</sub>. Even if all of these peaks are regarded as 1 $\alpha$ ,25D<sub>3</sub>, the amount of 1 $\alpha$ ,25D<sub>3</sub>

produced in cells is very small, and the observed phenomena are mainly attributed to 25D<sub>3</sub> itself. In addition, siRNA studies have strongly suggested that 25D<sub>3</sub> directly binds to VDR and acts almost independently of CYP27B1. Furthermore, based on a comprehensive analysis of gene expression using DNA microarray and real-time PCR approaches, *cystatin D*, *cystatin E/M*, and *semaphorin 3B* are each involved in the inhibitory effects of 25D<sub>3</sub> on cell proliferation. In other words, 25D<sub>3</sub> is presumed to control the expression of various genes and suppress cell proliferation by genomic action, i.e., by binding to VDR as a ligand in PZ-HPV-7 cells [13]. This suggests that in humans, the direct effect of 25D<sub>3</sub> can explain the risk of prostate cancer and the 25D<sub>3</sub> concentration in the blood shows a negative correlation with cancer risk (Figure 1).



1 $\alpha$ ,25D<sub>3</sub> is not detected in the blood of *Cyp27b1* knockout mouse, which exhibit an osteogenesis deficiency, uterine hypoplasia, immune dysfunction, etc. *Cyp27b1* knockout mice can be treated successfully by the administration of 1 $\alpha$ ,25D<sub>3</sub>, indicating that 1 $\alpha$ ,25D<sub>3</sub> plays important roles in bone formation, uterus formation, immune function, and other processes. Rowling *et al.* found a remarkable increase in the 25D<sub>3</sub> concentrations, blood calcium concentration, and bone density after the administration of vitamin D<sub>3</sub> to *Cyp27b1* knockout mouse, suggesting a direct effect of 25D<sub>3</sub>. However, since the weight, size, and capacity of the spinal column are considerably smaller than those of wild-type mice, they deduced that it is not possible to compensate for the effects of 1 $\alpha$ ,25D<sub>3</sub> with only 25D<sub>3</sub> [14,15]. Asano *et al.* reported a non-genomic action in which 25D<sub>3</sub> suppresses the

expression of the *sterol regulatory element-binding protein (SREBP)* gene, an important transcription factor in lipid cholesterol and fatty acid biosynthesis, directly, without VDR [16]. In addition, in a comparative analysis, Hirota *et al.* found that hair loss observed in *Vdr* knockout mice was not observed in *Cyp27b1* knockout mice. These results suggest that 25D<sub>3</sub> has a genomic action responsible for the maintenance of the hair cycle in the hair matrix via *Vdr*. Furthermore, abnormal chondrogenesis was less frequent in *Vdr* knockout mice than in *Cyp27b1* knockout mice. *Vdr* knockout mouse phenotypes are thought to be explained by non-genomic effects in which 1 $\alpha$ ,25D<sub>3</sub>, which does not interact with *Vdr*, but is abundant in the blood, directly controls the proliferation of chondrocytes [17].

Based on previous findings, Sakaki proposed that the physiological action of vitamin D is the sum of the effects of the "strong hormone 1 $\alpha$ , 25D<sub>3</sub> and weak hormone 25D<sub>3</sub>, and the contribution of both is different depending on the organ and cell" [9]. Additionally, 1 $\alpha$ ,25D<sub>3</sub> is a powerful hormone produced in small quantities in an emergency, assuming that 25D<sub>3</sub> is responsible for vitamin activity. In future vitamin D research, it is necessary to elucidate its comprehensive functions *in vivo* by clarifying the genomic and non-genomic actions of 25D<sub>3</sub>.

## References

1. Daiger SP, Schanfield MS, Sforza LL (1975) Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. *Proc Natl Acad Sci* 72: 2076-2080.
2. Baker AR, McDonnell DP, Hughes M (1988) Cloning and expression of full-length cDNA encoding human vitamin D receptor. *Proc Natl Acad Sci* 85: 3294-3298.
3. Kliewer SA, Umesono K, Mangelsdorf DJ (1992) Retinoid X receptor interacts with nuclear receptors in retinoic acid thyroid hormone and vitamin D<sub>3</sub> signaling. *Nature* 355: 446-449.
4. Rachez C, Freedman LP (2000) Mechanisms of gene regulation by vitamin D<sub>3</sub> receptor: a network of coactivator interactions. *Gene* 246: 9-21.
5. Darwish H, DeLuca HF (1993) Vitamin D-regulated gene expression. *Crit Rev Eukaryot Gene Exp* 3: 89-116.
6. Mizwicki MT, Norman AW (2009) The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signalling. *Sci Signal* 2: 275-276.
7. Fleet JC (2004) Rapid membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean? *J Nutr* 134: 3215-3218.
8. Mutair AN, Nasrat GH, Russell DW (2012) Mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family with severe vitamin D deficiency. *J Clin Endocrinol Metab* 92: 3177-3182.
9. Sakaki T (2015) Reconsideration of molecular mechanism of vitamin D action based on its metabolism. *J Jpn Biochem Soc* 87: 438-444.
10. Peng X, Hawthorne M, Vaishnav M, Arnaud R, Mehta RG (2009) 25-Hydroxyvitamin D<sub>3</sub> is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. *Breast Cancer Res Treat* 113: 31-41.
11. Ritter CS, Armbrrecht HJ, Slatopolsky E, Brown AJ (2006) 25-Hydroxyvitamin D<sub>3</sub> suppresses PTH synthesis and secretion by bovine parathyroid cells. *Kidney Int* 70: 654-659.
12. Munetsuna E, Nakabayashi S, Kawanami R, Yasuda K, Ohta M, et al. (2011) Mechanism of the Anti-proliferative Action of 25-Hydroxy-19-nor-vitamin D<sub>3</sub> in Human Prostate Cells. *J Mol Endocrinol* 47: 209-218.
13. Munetsuna E, Kawanami R, Nishikawa M, Ikeda S, Nakabayashi S (2014) Anti-proliferative activity of 25-hydroxyvitamin D<sub>3</sub> in human prostate cells. *Mol Cell Endocrinol* 382: 960-970.
14. Rowling MJ, Gliniak C, Welsh J, Fleet JC (2007) High dietary vitamin D prevents hypocalcemia and osteomalacia in CYP27B1 knockout mice. *J Nutr* 137: 2608-2615.
15. Zhang ZL, Ding XF, Tong J, Li BY (2011) Partial rescue of the phenotype in 1 $\alpha$ -hydroxylase gene knockout mice by vitamin D<sub>3</sub> injection. *Endocr Res* 36: 101-108.
16. Asano L, Watanabe M, Ryoden Y, Usuda K, Yamaguchi T (2017) Vitamin D Metabolite, 25-Hydroxyvitamin D, Regulates Lipid Metabolism by Inducing Degradation of SREBP/SCAP. *Cell Chem Biol* 24: 207-217.
17. Hirota Y, Nakagawa K, Mimatsu S, Sawada N, Sakaki T (2017) Nongenomic effects of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> on cartilage formation deduced from comparisons between Cyp27b1 and Vdr knockout mice. *Biochem Biophys Res Commun* 483: 359-365.